scholarly article | Q13442814 |
P50 | author | Elsebeth Lynge | Q39066029 |
Sisse Helle Njor | Q47497377 | ||
P2093 | author name string | Sisse Helle Njor | |
Anna-Belle Beau | |||
Ilse Vejborg | |||
Søren Nymand Lophaven | |||
P2860 | cites work | Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England | Q24629668 |
Breast Cancer Screening in Denmark | Q28735935 | ||
Breast cancer mortality in organised mammography screening in Denmark: comparative study | Q33751149 | ||
Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study | Q33768755 | ||
Modern mammography screening and breast cancer mortality: population study | Q33770344 | ||
Interpreting overdiagnosis estimates in population-based mammography screening | Q34195837 | ||
Long-term effects of mammography screening: updated overview of the Swedish randomised trials | Q34579899 | ||
Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program | Q34890406 | ||
Overdiagnosis of breast cancer in the Norwegian Breast Cancer Screening Program estimated by the Norwegian Women and Cancer cohort study | Q35078776 | ||
Regional trends in breast cancer incidence and mortality in Denmark prior to mammographic screening | Q36079460 | ||
Overdiagnosis in screening mammography in Denmark: population based cohort study | Q36638777 | ||
Overdiagnosis among women attending a population-based mammography screening program. | Q37001743 | ||
Balancing the benefits and detriments among women targeted by the Norwegian Breast Cancer Screening Program. | Q39949342 | ||
Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. | Q50665087 | ||
The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. | Q50701745 | ||
Decline in breast cancer mortality: how much is attributable to screening? | Q53161042 | ||
The benefits and harms of breast cancer screening: an independent review | Q57131263 | ||
Over-diagnosis estimate from The Independent UK Panel on Breast Cancer Screening is based on unsuitable data | Q59072557 | ||
Summary of the Evidence of Breast Cancer Service Screening Outcomes in Europe and First Estimate of the Benefit and Harm Balance Sheet | Q59073013 | ||
Extra incidence caused by mammographic screening | Q61881702 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | breast cancer screening | Q17011492 |
P304 | page(s) | 512-518 | |
P577 | publication date | 2017-05-03 | |
P1433 | published in | International Journal of Cancer | Q332492 |
P1476 | title | Benefit-to-harm ratio of the Danish breast cancer screening programme | |
P478 | volume | 141 |
Q99626163 | Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark |
Q100736997 | In situ breast cancer incidence patterns in Iceland and differences in ductal carcinoma in situ treatment compared to Sweden |
Q88933206 | Online information about risks and benefits of screening mammography in 10 European countries: An observational Web sites analysis |
Q47241923 | Outcome of breast cancer screening in Denmark |
Search more.